Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Noble Capital initiated coverage of Gyre Therapeutics (GYRE) with an Outperform rating. Gyre is developing drugs for inflammatory diseases that ...

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.

Currently, patients with this disease only have two FDA-approved treatments — nintedanib (Ofev, Boehringer Ingelheim) and pirfenidone (Esbriet, Genentech) — both of which could use improvement ...